Lindy Durrant

Lindy Durrant is a biochemist and cancer immunotherapy expert with extensive experience in academia and biotechnology. As Joint CEO and CSO at Scancell Limited since January 1996, Lindy Durrant has contributed to the development of innovative cancer immunotherapies. In addition, Lindy Durrant has served as a Professor of Cancer Immunotherapy at The University of Nottingham since December 1983, leading the Nottingham University Therapeutic Antibody Centre in the production of monoclonal antibodies for cancer treatment. Lindy Durrant's academic career also includes roles such as Reader, Senior Lecturer, Lecturer, and various scientific positions. Before joining The University of Nottingham, Lindy Durrant worked as a Postdoctoral Scientist at The University of Manchester. Lindy Durrant holds a Bachelor of Science in Biochemistry and a Doctor of Philosophy in Medicine from The University of Manchester.